Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Y. Dauvilliers, RK. Bogan, K. Šonka, M. Partinen, N. Foldvary-Schaefer, MJ. Thorpy

. 2022 ; 14 (-) : 531-546. [pub] 20220329

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017510

Lower-sodium oxybate (LXB) is an oxybate medication approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy 7 years of age and older in the United States. LXB was developed as an alternative to sodium oxybate (SXB), because the incidence of cardiovascular comorbidities is higher in patients with narcolepsy and there is an elevated cardiovascular risk associated with high sodium consumption. LXB has a unique formulation of calcium, magnesium, potassium, and sodium ions, containing 92% less sodium than SXB. Whereas the active oxybate moiety is the same for LXB and SXB, their pharmacokinetic profiles are not bioequivalent; therefore, a phase 3 trial in participants with narcolepsy was conducted for LXB. This review summarizes the background on oxybate as a therapeutic agent and its potential mechanism of action on the gamma-aminobutyric acid type B (GABAB) receptor at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons. The rationale leading to the development of LXB as a lower-sodium alternative to SXB and the key efficacy and safety data supporting its approval for both adult and pediatric patients with narcolepsy are also discussed. LXB was approved in August 2021 in the United States for the treatment of idiopathic hypersomnia in adults. Potential future developments in the field of oxybate medications may include novel formulations and expanded indications for other diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017510
003      
CZ-PrNML
005      
20220720100245.0
007      
ta
008      
220718s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/NSS.S279345 $2 doi
035    __
$a (PubMed)35378745
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Dauvilliers, Yves $u Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France $u University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France $1 https://orcid.org/0000000306836506
245    10
$a Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy / $c Y. Dauvilliers, RK. Bogan, K. Šonka, M. Partinen, N. Foldvary-Schaefer, MJ. Thorpy
520    9_
$a Lower-sodium oxybate (LXB) is an oxybate medication approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy 7 years of age and older in the United States. LXB was developed as an alternative to sodium oxybate (SXB), because the incidence of cardiovascular comorbidities is higher in patients with narcolepsy and there is an elevated cardiovascular risk associated with high sodium consumption. LXB has a unique formulation of calcium, magnesium, potassium, and sodium ions, containing 92% less sodium than SXB. Whereas the active oxybate moiety is the same for LXB and SXB, their pharmacokinetic profiles are not bioequivalent; therefore, a phase 3 trial in participants with narcolepsy was conducted for LXB. This review summarizes the background on oxybate as a therapeutic agent and its potential mechanism of action on the gamma-aminobutyric acid type B (GABAB) receptor at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons. The rationale leading to the development of LXB as a lower-sodium alternative to SXB and the key efficacy and safety data supporting its approval for both adult and pediatric patients with narcolepsy are also discussed. LXB was approved in August 2021 in the United States for the treatment of idiopathic hypersomnia in adults. Potential future developments in the field of oxybate medications may include novel formulations and expanded indications for other diseases.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bogan, Richard K $u University of South Carolina School of Medicine, Columbia, SC, USA $1 https://orcid.org/0000000170432974
700    1_
$a Šonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000157739656 $7 jn99240001644
700    1_
$a Partinen, Markku $u Helsinki Sleep Clinic, Terveystalo Healthcare, and Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland $1 https://orcid.org/0000000281829368
700    1_
$a Foldvary-Schaefer, Nancy $u Sleep Disorders Center, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000189003280
700    1_
$a Thorpy, Michael J $u Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
773    0_
$w MED00189562 $t Nature and science of sleep $x 1179-1608 $g Roč. 14, č. - (2022), s. 531-546
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35378745 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100241 $b ABA008
999    __
$a ind $b bmc $g 1816621 $s 1168752
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c - $d 531-546 $e 20220329 $i 1179-1608 $m Nature and science of sleep $n Nat. sci. sleep $x MED00189562
LZP    __
$a Pubmed-20220718

Najít záznam

Citační ukazatele

Možnosti archivace